CEO Peter Luo bought a small $85K stake (+15% ownership) with the stock above MA20/MA50 in a healthcare sector beating SPY by ~11%. But price is up 216% off its 52w low and now 12.6% above the insider's buy price, so most of the edge is gone; sub-$100K size and no cluster keep this a small watchlist-tier position.
Watch: Unprofitable biotech, negative FCF; price extended far above 52w low; buy size below $100K threshold; single insider only.